GLPG2222 Plus Kalydeco Shows Positive Clinical Results in Phase 2 Trial, Galapagos Reports
Adding investigational CFTR corrector GLPG2222 safely improved disease parameters in cystic fibrosis (CF) patients treated with Kalydeco...
Galapagos Cystic Fibrosis Drug Enters Phase I, Triggering €8.5M Payout
Galapagos will receive a $10M (€8.5M) milestone payment from its collaborator, AbbVie, after their cystic fibrosis candidate started a...
Supine posture changes lung volumes and increases ventilation heterogeneity in cystic fibrosis
Abstract Introduction Lung Clearance Index (LCI) is recognised as an early marker of cystic fibrosis (CF) lung disease. The effect of...
Advances in the Prevention and Treatment of MRSA in Patients with Cystic Fibrosis
Active research and special expertise at Cleveland Clinic’s Adult CF Center Methicillin-resistant Staphylococcus aureus (MRSA) increases...
Galapagos Initiates Phase 1 Trial to Evaluate CF Corrector GLP3221 in Healthy Volunteers
Galapagos has initiated a Phase 1 clinical trial in healthy volunteers to evaluate a new C2 corrector, called GLPG3221, developed for the...
Spyryx Presents Data Ably Supporting SPX-101 as Potential Treatment for All CF Patients
Spyryx Biosciences recently presented preclinical data supporting the clinical benefits of its cystic fibrosis (CF) treatment candidate...
Sclerosis medicine can fight multi-resistant bacteria
A surprising discovery shows that a widely used and 20-year-old medicine used to treat multiple sclerosis can also beat a type of...
Virtual reality used during cystic fibrosis treatment
Virtual reality headsets like this one allow the viewer to immerse themselves in another setting Virtual reality headsets are being used...
Tezacaftor-ivacaftor improves pulmonary function in cystic fibrosis patients: The EVOLVE trial
1. Tezacaftor-Ivacaftor significantly improves lung function and reduces the frequency of pulmonary exacerbations in cystic fibrosis (CF)...
